Clinical Trial Update: A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers [Phase 1]

View source ↗

Summary

Phase 1 trial update for IOA-244, a PI3Kδ inhibitor, being studied in metastatic cancers with status currently ACTIVE_NOT_RECRUITING.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis
• Non-hodgkin Lymphoma
• Non-small Cell Lung Cancer
• Solid Tumors
• Uveal Melanoma

Drugs mentioned

• IOA-244 (IOA-244)

Snippet

Sponsor: iOnctura | Conditions: Solid Tumor, Adult, Non-Hodgkin Lymphoma, Adult | Phase 1 | Status: ACTIVE_NOT_RECRUITING